This website is intended for healthcare professionals only.
REDEFINING 3L mCRC LANDSCAPE WITH
THE ARRIVAL OF COMBINATION THERAPIES
Prof. Gerald Prager, Director of the GI cancer program of the department of medical oncology, Medical University of Vienna and Comprehensive Cancer Center, Vienna.
Vienna, Austria
This webinar focuses on combination therapies in mCRC treatment – to optimize overall survival and improve patients’ quality of life. Interactive poll questions are proposed during the live presentation to enable participants to share their daily experiences and drive insightful exchanges.
Indication: mCRC
Key points covered
This webinar highlights the advantages of combination therapies in 3L mCRC. It covers the following points:
• The newly approved FTD/TPI + bevacizumab combination therapy significantly improves OS and PFS, as well as ECOG PS, GHS, and QoL, compared with FTD/TPI alone.
• FTD/TPI + bevacizumab safety profile is manageable and consistent with individual safety profiles of both treatments.
• In specific cases, monotherapy could still be relevant.
Webinar Replay
Featured Speaker
Professor Gerald Prager
Prof Prager is the Director of the GI Cancer Program of the Department of Medical Oncology at the Medical University of Vienna and Comprehensive Cancer Center, Vienna. He leads the Unit for Precision Medicine in Cancer and is an Associate Professor of Medicine, Board Certified for Internal Medicine, Hematology, and Medical Oncology. Prof Prager graduated from the Medical School of the University of Vienna and completed his postdoctoral training at the University of California, San Diego, USA and was a Visiting Professor at the Norris Cancer Center, University of Southern California, Los Angeles, USA in 2011. Prof Prager’s main research interests focus on translational research and (tumor-) angiogenesis and his works have been honored by more than 20 international awards and published in highly renowned international journals. Prof Prager is also a member of the ESMO Scientific Committee.
